Related Experiment Video
Updated: Jul 6, 2026
15:17
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
14.5K
Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence
Adel T Aref1, Mohashin Pathan1, Rosemary Habib2
1ProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.
Summary
A new six-protein risk score improves prognosis for stage-III colorectal cancer (CC) patients. This proteomic biomarker enhances risk stratification beyond standard clinical factors, aiding in personalized treatment decisions.
Area of Science:
- Oncology
- Proteomics
- Biomarker Discovery
Background:
- Stage-III colorectal cancer (CC) lacks effective prognostic biomarkers for recurrence risk.
- Proteomic profiling offers a quantitative method for improved risk stratification in CC.
Purpose of the Study:
- To develop and validate a proteomic-based risk score for predicting recurrence in stage-III CC.
- To assess the added prognostic value of the proteomic score to existing clinical factors.
Main Methods:
- Proteomic analysis using data-independent acquisition mass spectrometry on stage-III CC tumor samples from three cohorts (n=759).
- Development of a six-protein risk score (ITIH1, PPIE, LTBP1, KPNA2, IGFBP7, CKAP4) using Cox regression in a training cohort.
- Validation of the risk score in two independent external cohorts.
Main Results:
- The six-protein risk score significantly stratified patients into high- and low-risk groups for recurrence across all cohorts (HRs ranging from 1.8 to 5.7).
- Integration of the proteomic score with clinical factors further improved prognostic accuracy.
- A subgroup of patients with very low recurrence risk was consistently identified.
Conclusions:
- The validated six-protein risk score enhances prognostic stratification for stage-III CC beyond standard clinical factors.
- This proteomic biomarker provides a framework for risk-adapted clinical investigation.
- Further research through prospective, treatment-stratified trials is needed to guide adjuvant therapy decisions.
More Related Videos
Related Concept Videos
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...